caretrace.iopowered by▸healthparse
SearchCohort Builder
Tools▾
KOL FinderTerritoriesDrug Compare
AI Query
Browse▾
By stateBy specialty
Pricing
SearchCohort BuilderToolsKOL FinderTerritoriesDrug CompareAI QueryBrowseBy stateBy specialtyPricing
PROVIDER PROFILE · NPI 1720248081

Roy ChenMD

Hematology-OncologyRiverhead, NYI
CROSS-REFERENCE

Related data on other Healthparse brands

ProviderScore
OIG/SAM exclusion screening, sanctions history
© 2026 CareTrace
PricingContactPrivacyTerms
REFERRAL NETWORK

Where Roy Chen's patients come from & go

Directional shared-patient flow from Medicare claims — who sends patients to this provider (inbound) and where this provider's patients go next (outbound). 9 inbound referrers · 0 outbound destinations.

Receives referrals from
Inbound — who sends patients here
PhysicianPatientsVisits
Quest Diagnostics Clinical Laboratories Inc
Clinical Laboratory · Melville, NY
59471
Inform Diagnostics, Inc.
Clinical Laboratory · Coppell, TX
2898
Yelda Nouri
Hematology-Oncology · Riverhead, NY
2474
CENTRAL SUFFOLK HOSPITAL2253
OSTROW, STANLEY1737
Laboratory Corporation Of America Holdings
Clinical Laboratory · Raritan, NJ
1549
Samir Patel
Hematology-Oncology · Newburgh, NY
1226
Stephen Vlay
Clinical Cardiac Electrophysiology · East Setauket, NY
1227
LONG ISLAND COMMUNITY HOSPITAL AT NYU LANGONE HEALTH1234
Refers patients to
Outbound — where patients go next
No outbound pairs above the suppression threshold.
Source: CMS Physician Shared Patient Patterns (30-day window, Medicare FFS). Direction = a beneficiary seen by the first provider, then the second, within 30 days; a proxy for referral, not a documented referral. Pairs with fewer than 11 shared beneficiaries are suppressed.
MEDICARE UTILIZATION · PART B · 2024
Total beneficiaries
26,549
Unique beneficiaries
—
Total services
218,865
Distinct HCPCS
128
Medicare payment
$2.1M
Peer benchmark
Q1
Q2
Q3
Q4
Q5
Total Medicare services vs. 628 Hematology-Oncology providers in NY — top quintile (cohort median 883).
QUALITY · MIPS · 2024
Final MIPS score
100.0
Quality
15.8
Cost
75.0
Improvement activities
40.0
Promoting interop.
100.0
Payment adjustment
1.05%
Group
PRESCRIBING · PART D · 2024
Total Rx claims
1,831
Beneficiaries
—
Total drug cost
$8.1M
Distinct drugs
57
Brand share
70.1%
Top prescribed drugs
Darbepoetin Alfa In Polysorbat217 claims
Apixaban118 claims
Denosumab99 claims
Fosnetupitant/Palonosetron70 claims
Leuprolide Acetate70 claims
INDUSTRY PAYMENTS · OPEN PAYMENTS · 2024
Total received
$129
Payment records
1
By payment type
Food and Beverage$129